Health
Amplia Therapeutics says ‘priming’ a tumour could improve outcomes for patients with pancreatic cancer – Small Caps
New research describing the fundamental biology behind Amplia Therapeutics’ (ASX: ATX) planned phase 2 clinical trial on pancreatic…
New research describing the fundamental biology behind Amplia Therapeutics (ASX: ATX) planned phase 2 clinical trial on pancreatic cancer patients has highlighted the potential benefits of using a focal adhesion kinase (FAK) inhibitor prior to administering…
Continue Reading
-
Noosa News14 hours agoMan charged over allegedly abandoning Arnie the German shepherd in car after claiming dog and vehicle were stolen
-
Noosa News15 hours agoMotorcyclist dies in crash with truck
-
Noosa News15 hours agoSomerville House investigating after teachers’ dossier on students leaked
-
General20 hours agoSmall-town cleaner finds himself in legal battle with EnduroShield over product packaging